Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N6O.2C3H6O2 |
| Molecular Weight | 496.5588 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(O)=O.CCC(O)=O.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=AFGQXWSHYUHHNV-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)
| Molecular Formula | C19H20N6O |
| Molecular Weight | 348.4017 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H6O2 |
| Molecular Weight | 74.0785 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4768 |
|||
Target ID: CHEMBL2966 |
|||
Target ID: CHEMBL220 |
590.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
| Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| Effects of imidocarb dipropionate in cats with chronic haemobartonellosis. | 2002 Summer |
|
| In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
| Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
| [Autochthonous babesiosis in dogs in the Netherlands?]. | 2004 May 1 |
|
| First isolation and molecular characterization of Ehrlichia canis in Spain. | 2004 Nov 10 |
|
| Detection and molecular characterization of a novel large Babesia species in a dog. | 2004 Oct 5 |
|
| [A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy]. | 2005 Dec 1 |
|
| Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
| Identification of anti-babesial activity for four ethnoveterinary plants in vitro. | 2005 Jun 10 |
|
| Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate. | 2005 Mar |
|
| Effective imidocarb dipropionate therapy for Babesia shortti in falcons. | 2006 Feb 18 |
|
| Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs. | 2006 Jul-Aug |
|
| Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis. | 2006 Jun 30 |
|
| Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
| Canine babesiosis in France. | 2006 May 31 |
|
| Chemotherapy against babesiosis. | 2006 May 31 |
|
| Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. | 2006 Winter |
|
| Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
| Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
| The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis. | 2009 |
|
| Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli). | 2009 Dec |
|
| Canine babesiosis: from molecular taxonomy to control. | 2009 Mar 26 |
|
| Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission. | 2009 Mar-Apr |
|
| Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
| Canine babesiosis in northern Portugal and molecular characterization of vector-borne co-infections. | 2010 Apr 8 |
|
| First case of babesiosis caused by Babesia canis canis in a dog from Norway. | 2010 Aug 4 |
|
| Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
Sample Use Guides
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:55 GMT 2025
by
admin
on
Mon Mar 31 18:13:55 GMT 2025
|
| Record UNII |
ZSM1M03SHC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 522.1156
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
||
|
CFR |
21 CFR 522.1155
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID4046604
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
Imidocarb dipropionate
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
1740238
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
9983292
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
259-791-8
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
C76007
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
55750-06-6
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
300000023751
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
C031719
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY | |||
|
DBSALT001684
Created by
admin on Mon Mar 31 18:13:56 GMT 2025 , Edited by admin on Mon Mar 31 18:13:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |